OTS - Eleva's drug candidate to be examined for use in Covid-19 treatment
2020. June 03. 10:00
Freiburg, Germany, 3 June, 2020 (APA/OTS) - Eleva, a manufacturer
of superior biologics, is exploring the potential of one of its
drug candidates for first-in-line therapy of Covid-19. The
compound, factor H, is part of the complement system, which is
believed to affect the severity of the course of Covid-19. Eleva
has developed factor H previously for a different indication and
taken it through pre-clinical stages.
The complement system is a vital part of the immune system. It
recognizes and destroys pathogens and protects the body's own cells
with a special component, factor H. Insufficient amounts of factor
H lead to excessive inflammation and risk of tissue damage.
Emerging evidence suggests that the lung tissue decay observed in
severe cases of Covid-19 could be caused by this unregulated
inflammation. Current means to inhibit this process use artificial
antibodies that block the pathway altogether, stopping the
inactivation of pathogens and causing a significant risk of
infection. Conversely, supplemented factor H allows for regu lated
defence while protecting the host cells.
Andreas Schaaf, CEO of Eleva, says: "Unlocking novel therapies
is our mission. This path deserves to be explored and may lead to
effective treatment of Covid-19."
Eleva has previously developed recombinant factor H for
glomerulopathy and taken it through pre-clinical stages. Studies
have indicated a significant reduction in inflammation and tissue
damage when factor H was supplemented. Eleva is now looking to
accelerate the Covid-19-specific evaluation with a pharmaceutical
partner.
About Eleva
Eleva develops novel biological therapies with its
pharmaceutical partners. The privately-held company leverages its
unique moss-based production platform to produce supreme biologics
like antibodies, replacement enzymes, or fusion toxins. Eleva has
successfully developed drug candidates into clinical phases.
Press contact
eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
+49 761 470 99 0
www.elevabiologics.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.